Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
ATMARINOMED6
Tue, 23.05.2023       Marinomed Biotech AG
ATMARINOMED6

Marinomed Biotech AG reports best first quarter in company history Q1 revenues up 38% to new record of € 3.3 million thanks to broadband virus blocker Carragelose Carragelose: Preparations for market entry in the USA and extension of use to allergic indications in full swing Marinosolv: Full focus on commercialization of product candidates Tacro [ … ]
Technical analysis
To the publication
Tue, 23.05.2023       Marinomed Biotech AG
ATMARINOMED6

Marinomed Biotech AG reports best first quarter in company history Q1 revenues up 38% to new record of € 3.3 million thanks to broadband virus blocker Carragelose Carragelose: Preparations for market entry in the USA and extension of use to allergic indications in full swing Marinosolv: Full focus on commercialization of product candidates Tacro [ … ]
Technical analysis
To the publication
Wed, 19.04.2023       Marinomed Biotech AG
ATMARINOMED6

 Marinomed Biotech AG with Carragelose record sales in 2022 and positive outlook for 2023 Carragelose revenues show double-digit growth for the fourth year in a row New growth opportunities driven by license agreement with Procter & Gamble, US patent for Marinosolv technology and expansion of Solv4U technology partnerships Outlook 2023: Movi [ … ]
Technical analysis
To the publication
Wed, 19.04.2023       Marinomed Biotech AG
ATMARINOMED6

 Marinomed Biotech AG with Carragelose record sales in 2022 and positive outlook for 2023 Carragelose revenues show double-digit growth for the fourth year in a row New growth opportunities driven by license agreement with Procter & Gamble, US patent for Marinosolv technology and expansion of Solv4U technology partnerships Outlook 2023: Movi [ … ]
Technical analysis
To the publication
Wed, 12.04.2023       Marinomed Biotech AG
ATMARINOMED6

Marinomed Biotech AG publishes clinical data on the effectiveness of its Carragelose nasal spray in the treatment of hay fever Carragelose nasal spray shows significant effectiveness in the prophylactic treatment of allergic rhinitis symptoms in the nose Clinical data extend the effectiveness of Carragelose from blocking respiratory viruses to p [ … ]
Technical analysis
To the publication
Wed, 12.04.2023       Marinomed Biotech AG
ATMARINOMED6

Marinomed Biotech AG publishes clinical data on the effectiveness of its Carragelose nasal spray in the treatment of hay fever Carragelose nasal spray shows significant effectiveness in the prophylactic treatment of allergic rhinitis symptoms in the nose Clinical data extend the effectiveness of Carragelose from blocking respiratory viruses to p [ … ]
Technical analysis
To the publication
Tue, 14.03.2023       Marinomed Biotech AG
ATMARINOMED6

  Marinomed Biotech AG reports positive clinical data for the Carragelose decongestant nasal spray Clinical data shows a significant decongestant effect of the Sorbitol-containing Carragelose nasal spray in allergic rhinitis patients The product utilizes the effect of Sorbitol as treatment of a blocked nose without the side effect of habituation [ … ]
Technical analysis
To the publication
Tue, 14.03.2023       Marinomed Biotech AG
ATMARINOMED6

  Marinomed Biotech AG reports positive clinical data for the Carragelose decongestant nasal spray Clinical data shows a significant decongestant effect of the Sorbitol-containing Carragelose nasal spray in allergic rhinitis patients The product utilizes the effect of Sorbitol as treatment of a blocked nose without the side effect of habituation [ … ]
Technical analysis
To the publication
Thu, 16.02.2023       Marinomed Biotech AG
ATMARINOMED6

  Marinomed Biotech AG announces preliminary revenue for 2022 with double-digit growth for Carragelose Major strategic developments in 2022 to boost future growth Preliminary revenues stable at € 11.3 m for 2022 (2021: € 11.6 m) despite lack of milestone payments in 2022 Adjusted for the milestone payment in 2021, underlying revenues have incr [ … ]
Technical analysis
To the publication
Thu, 16.02.2023       Marinomed Biotech AG
ATMARINOMED6

  Marinomed Biotech AG announces preliminary revenue for 2022 with double-digit growth for Carragelose Major strategic developments in 2022 to boost future growth Preliminary revenues stable at € 11.3 m for 2022 (2021: € 11.6 m) despite lack of milestone payments in 2022 Adjusted for the milestone payment in 2021, underlying revenues have incr [ … ]
Technical analysis
To the publication

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

Legend/Explanation
The newswire feed is updated several times a day. To make sure you don't miss any news, please check back here often. If you are curious about a headline or want to find out more about a publication, click on it to go to the preview and click again to go to the full news item.
Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Friday, 18.10.2024, Calendar Week 42, 292nd day of the year, 74 days remaining until EoY.